Search results for " BIOMARKERS"

showing 10 items of 365 documents

Biomarkers of aging

2010

Aging is a complex process that negatively impacts the development of the different systems and its ability to function. Moreover, the Aging rate in humans is not the same, principally due to genetic heterogeneity and environmental factors. The aging rate is measured as the decline of functional capacity and stress resistance. Therefore, several attempts have been made to analyse the individual age, ( so-called biological age) compared to chronological age. The biomarkers of aging are age-related body function or composition, these markers aim to assess the biological age and predict the onset of age-related diseases and/or residual lifetime. Such biomarkers should help in one hand to chara…

Settore MED/04 - Patologia GeneraleSettore MED/05 - Patologia ClinicaImmunosenescence Aging Inflammation biomarkers
researchProduct

Endothelial Progenitor Cells A New Real Hope?

2017

Chronic inflammatory diseases, such as cardiovascular diseases (CVDs), diabetes, Alzheimer’s disease (AD) and cancer, have a disproportionate prevalence with advancing age owing to the continuous growth in the aging population. This condition determines several medical, economic and social problems due to the dramatic increase in the number of affected individuals, who are not autonomous. Thus, research efforts are centred around reducing and/or delaying the onset and progression of these diseases by researching new strategies for early prevention and diagnosis. In this context, understanding the mechanisms involved in the tissue, organ protection and repair are imperative for the developme…

Settore MED/05 - Patologia ClinicaEndothelial progenitor cells biomarkers therapeutic agents age-related diseases
researchProduct

Biomarkers and Inflammatory Network in Aging: Targets for Therapies

2013

Settore MED/05 - Patologia Clinicainflammation ageing biomarkers
researchProduct

Comparison of Right Ventricular Longitudinal Strain Imaging, Tricuspid Annular Plane Systolic Excursion, and Cardiac Biomarkers for Early Diagnosis o…

2010

Objectives: The aim was to determine the role of assessing right ventricular (RV) function, using standard echocardiography and Doppler myocardial imaging (DMI), in the early diagnosis of cardiac amyloidosis (CA) and in prediction of mortality. Methods: A total of 249 patients with AL amyloidosis were categorized on the basis of left ventricular thickness and E' velocity, and compared to 38 age- and sex-matched controls. Standard echocardiographic parameters of RV function were assessed, and longitudinal systolic myocardial velocity, strain rate (sSR), and strain (sS) were determined for the basal and middle RV free wall segments. Patients were followed for the endpoint of mortality. Result…

Settore MED/09 - Medicina InternaCardiac Amyloidosis Echocardiography Cardiac biomarkers
researchProduct

Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

2023

Introduction: Lomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest. This study aimed to determine the long-term hepatic safety of lomitapide. Methods: Data were aggregated from the pivotal phase 3 and extension phase clinical trial with lomitapide (median 5.1 years; serum total bilirubin, transaminases, cytokeratin-18 [CK-18] and enhanced liver fibrosis [ELF] score, fat-soluble vitamins and essential fatty acids), 8-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) and real-world evidence f…

Settore MED/09 - Medicina Internahepatic steatosisliverLomitapidehepatic biomarkershepatic steatosiSettore BIO/18 - Geneticahepatic biomarkerSettore BIO/14 - Farmacologialiver fibrosis.hepatichepatic; hepatic biomarkers; hepatic steatosis; homozygous familial hypercholesterolaemia; liver; liver fibrosis; lomitapidehomozygous familial hypercholesterolaemialiver fibrosis
researchProduct

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

2021

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes. In the current clinical practice, LB is used for the identification of driver mutations in circulating tumor DNA derived from both tumor tissue and circulating neoplastic cells. As suggested by a growing body of evidence, however, there are several clinical settings where biological samples other than tissue could be used in the routine practice to identify potentially predictive biomarkers of either response or resistance to targeted treatments. New applications are emerging as useful clinical tools, and o…

Societies ScientificCancer ResearchContext (language use)ReviewNeoplastic CellsBioinformaticsCirculating tumor cellCirculatingBiomarkers TumorMedicineHumansDigital polymerase chain reactionLiquid biopsycfDNAcirculating tumor DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCRTumorCirculating Neoplastic Cellsliquid biopsybusiness.industrydigital PCRScientificctDNAcirculating cell-free DNANeoplastic Cells CirculatingCirculating Cell-Free DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCR; Biomarkers Tumor; Humans; Italy; Liquid Biopsy; Neoplastic Cells Circulating; Societies ScientificOncologyItalyCirculating tumor DNAPosition papernext-generation sequencingSocietiesbusinessreal-time PCRBiomarkersHuman
researchProduct

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societi…

2021

The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the r…

Societies ScientificGenomic profilingDruggabilityNTRK-FusionsMedical OncologyNeoplasmsMedicineHumansAgnostic biomarkersPrecision MedicineHistology-agnosticTumor histologybusiness.industryAgnostic biomarkers; Agnostic drugs; Histology-agnostic; Homologous recombination deficiency; Microsatellite instability; Mismatch repair deficiency; NTRK-Fusions; Precision oncology; Humans; Italy; Medical Oncology; Precision Medicine; Neoplasms; Societies ScientificScientificPrecision oncologyHematologyPrecision medicineData scienceAgnostic drugsOncologyEconomic sustainabilityItalyAgnostic biomarkerMicrosatellite instabilityPosition paperNeoplasmIdentification (biology)Personalized medicineAgnostic drugNTRK-FusionbusinessSocietiesHomologous recombination deficiencyMismatch repair deficiencyHuman
researchProduct

Monitoring response to treatment in asthma management: food for thought

2004

Asthma is a chronic inflammatory disorder of the airways that is characterized by episodic symptoms. In this regard, asthma management has classically involved periodic re-assessment by the health-care provider, during which therapy is altered mainly based on clinical and physiological parameters, such as assessment of symptoms, spirometry and peak expiratory flow monitoring. In this context, various markers of airway inflammation (e.g. eosinophils in the induced sputum, nitric oxide in the exhaled air) have been proposed to assess the severity of asthma and to adjust the therapy accordingly. The evaluation of airway hyper-responsiveness with different stimuli has also been suggested as a n…

Spirometrymedicine.medical_specialtyAllergyImmunologyBronchiPeak Expiratory Flow RateContext (language use)Settore MED/10 - Malattie Dell'Apparato RespiratorioSensitivity and SpecificityBronchial Provocation TestsQuality of lifeSurveys and QuestionnairesmedicineHumansImmunology and AllergyIntensive care medicineLungAsthmamedicine.diagnostic_testbusiness.industryRespiratory diseaseSputummedicine.diseaseAsthmarespiratory tract diseasesTreatment OutcomeBreath TestsSpirometryChronic DiseaseImmunologyQuality of LifeSputumasthma treatment biomarkersmedicine.symptombusinessAirway
researchProduct

Genetic contribution in sporadic thoracic aortic aneurysm? Emerging evidence of genetic variants related to TLR-4-mediated signaling pathway as risk …

2015

Abstract Sporadic thoracic aortic aneurysms (TAA) and dissections are one of the major causes of morbidity and mortality worldwide, especially in those older than 65 years. The presentation of TAA is varied and often silent. Thus, sporadic TAA detection is often fortuitous, with identification occurring during a routine physical examination or during an unrelated medical evaluation. Once suspected, confirmation by imaging clinical approaches is needed to allow the choose of the unique treatments for TAA, namely the surgery procedures, including elective surgery or endovascular repair before the onset of catastrophic and fatal complications, such as dissection or rupture. At present, there a…

Sporadic thoracic aortic aneurysms (TAA) and dissections genetic variants biomarkers targets for new personalized therapeutic treatments.Pathologymedicine.medical_specialtyPhysiologyDiseaseBioinformaticscomplex mixturesThoracic aortic aneurysmRisk Factorsparasitic diseasesGenetic variationMedicineHumansGenetic Predisposition to DiseaseElective surgeryPharmacologyAortic Aneurysm Thoracicbusiness.industryGenetic variantsGenetic VariationMedical evaluationmedicine.diseasedigestive system diseasesToll-Like Receptor 4DissectionMolecular MedicineSignal transductionbusinessSignal TransductionVascular pharmacology
researchProduct

GHB related acids are useful in routine casework of suspected GHB intoxication cases

2021

Abstract GHB related acids (3,4-dihydroxy butyric acid, 2,4-dihydroxy butyric acid and glycolic acid) are produced through oxidative GHB metabolism. These analytes could be potential biomarkers to ensure the diagnosis of a GHB intoxication and even prolong the detection window. Within this study, forensic routine cases were measured to consider the potential of additional gas chromatographic mass spectrometric analysis on these acids. 17 GHB positive real cases (10 serum samples and 7 urine samples) and 40 cases with suspicion of drugging in DFC cases and negative GHB results (21 serum samples and 19 urine samples) were evaluated. Increased GHB related acid concentrations were detected in a…

Succinic AcidUrinePharmacology01 natural sciencesGas Chromatography-Mass SpectrometryPathology and Forensic MedicineButyric acidForensic Toxicology03 medical and health scienceschemistry.chemical_compoundα oxidation0302 clinical medicineHumansMedicine030216 legal & forensic medicineGlycolic acidbusiness.industryPoisoning010401 analytical chemistrySerum samplesMass spectrometricGlycolates0104 chemical scienceschemistryPotential biomarkersButyric AcidSodium OxybatebusinessLawBiomarkersForensic Science International
researchProduct